Citigroup Inc Immuneering Corp Transaction History

Citigroup Inc

$196 Billion
Q2 2025

A detailed history of Citigroup Inc transactions in Immuneering Corp stock. As of the latest transaction made, Citigroup Inc holds 796 shares of IMRX stock, worth $4,600. This represents 0.0% of its overall portfolio holdings.

Number of Shares

796

Previous 796 -0.0%

Holding current value

$4,600

Previous $1,000 100.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	SELL	$1.46 - $2.36 $2,191 - $3,542	-1,501 Reduced 65.35%	796 $1,000
Q4 2024 Feb 12, 2025	BUY	$1.62 - $2.47 $2,431 - $3,707	1,501 Added 188.57%	2,297 $5,000
Q3 2024 Nov 12, 2024	SELL	$1.03 - $3.21 $4,007 - $12,490	-3,891 Reduced 83.02%	796 $1,000
Q2 2024 Aug 12, 2024	SELL	$1.28 - $2.75 $1,025 - $2,202	-801 Reduced 14.6%	4,687 $5,000
Q1 2024 May 10, 2024	BUY	$1.91 - $7.32 $3,287 - $12,597	1,721 Added 45.69%	5,488 $15,000
Q4 2023 Feb 09, 2024	BUY	$4.84 - $8.44 $14,897 - $25,978	3,078 Added 446.73%	3,767 $27,000
Q3 2023 Nov 09, 2023	SELL	$7.21 - $10.68 $42,156 - $62,445	-5,847 Reduced 89.46%	689 $5,000
Q2 2023 Aug 10, 2023	BUY	$6.49 - $13.36 $40,471 - $83,312	6,236 Added 2078.67%	6,536 $66,000
Q1 2023 May 11, 2023	SELL	$3.78 - $10.38 $389 - $1,069	-103 Reduced 25.56%	300 $2,000
Q4 2022 Feb 09, 2023	SELL	$4.09 - $15.0 $15,566 - $57,090	-3,806 Reduced 90.43%	403 $1,000
Q3 2022 Nov 10, 2022	BUY	$5.0 - $14.32 $16,400 - $46,969	3,280 Added 353.07%	4,209 $60,000
Q2 2022 Aug 10, 2022	SELL	$3.89 - $7.81 $2,330 - $4,678	-599 Reduced 39.2%	929 $6,000
Q1 2022 May 12, 2022	SELL	$6.47 - $16.99 $9,252 - $24,295	-1,430 Reduced 48.34%	1,528 $9,000
Q4 2021 Feb 10, 2022	BUY	$16.12 - $31.02 $27,597 - $53,106	1,712 Added 137.4%	2,958 $48,000
Q3 2021 Nov 10, 2021	BUY	$17.0 - $32.84 $21,182 - $40,918	1,246 New	1,246 $33,000

Others Institutions Holding IMRX

# of Institutions

Shares Held

4.08M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $153M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account